Your browser is no longer supported. Please, upgrade your browser.
Settings
RGLS Regulus Therapeutics Inc. daily Stock Chart
RGLS [NASD]
Regulus Therapeutics Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own11.38% Shs Outstand106.67M Perf Week-6.94%
Market Cap20.31M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float92.96M Perf Month-33.61%
Income-23.90M PEG- EPS next Q-0.10 Inst Own50.20% Short Float0.50% Perf Quarter-72.61%
Sales0.07M P/S282.08 EPS this Y69.40% Inst Trans-3.37% Short Ratio0.35 Perf Half Y-76.53%
Book/sh0.10 P/B1.90 EPS next Y31.00% ROA-86.00% Target Price- Perf Year-85.68%
Cash/sh0.31 P/C0.62 EPS next 5Y39.60% ROE-205.40% 52W Range0.17 - 1.52 Perf YTD-81.69%
Dividend- P/FCF- EPS past 5Y25.90% ROI- 52W High-87.74% Beta1.38
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low9.58% ATR0.03
Employees63 Current Ratio1.30 Sales Q/Q0.00% Oper. Margin- RSI (14)34.23 Volatility10.52% 12.42%
OptionableYes Debt/Eq1.91 EPS Q/Q67.30% Profit Margin- Rel Volume0.34 Prev Close0.19
ShortableYes LT Debt/Eq0.00 EarningsAug 07 Payout- Avg Volume1.35M Price0.19
Recom3.00 SMA20-19.27% SMA50-27.33% SMA200-74.60% Volume459,809 Change-2.10%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Sep-19-18 02:22PM  Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)? Simply Wall St.
Aug-23-18 12:50PM  These Biotech Stocks Are Moving Higher in August ACCESSWIRE
Aug-09-18 06:10PM  Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates Zacks -9.42%
05:05PM  Regulus: 2Q Earnings Snapshot Associated Press
04:05PM  Regulus Reports Second Quarter 2018 Financial Results and Recent Updates PR Newswire
Jul-09-18 09:13AM  Regulus Stock Plunges on Cash Concerns Despite Restructuring Zacks
Jul-05-18 05:00PM  Regulus Announces Strategic Update and Corporate Restructuring PR Newswire
07:35AM  Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities ACCESSWIRE
Jul-03-18 12:38PM  Gaithersburg biotech raising $1M to stop cancer tumors in their tracks American City Business Journals
Jun-12-18 07:45AM  New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-17-18 07:40AM  Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-10-18 11:46PM  Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
05:08PM  Regulus: 1Q Earnings Snapshot Associated Press
04:10PM  Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress PR Newswire
May-03-18 04:15PM  Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018 PR Newswire
May-01-18 08:30AM  Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD PR Newswire
Apr-17-18 04:10PM  Kathryn J. Collier Joins Regulus Board of Directors PR Newswire
Mar-20-18 04:15PM  Regulus to Present at the Needham Healthcare Conference PR Newswire
Mar-09-18 12:11AM  Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT Thomson Reuters StreetEvents +12.18%
Mar-07-18 04:31PM  Regulus reports 4Q loss Associated Press
04:10PM  Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
06:35AM  Was Regulus Therapeutics Incs (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
Mar-05-18 07:01PM  Regulus to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Mar-02-18 08:00AM  New Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire +9.26%
Feb-28-18 04:15PM  Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018 PR Newswire -5.13%
Feb-22-18 02:23AM  WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration PR Newswire
Feb-08-18 04:15PM  Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-05-18 08:00AM  Analysis: Positioning to Benefit within Churchill Downs, Airgain, Fortune Brands Home & Security, Kemper, Perficient, and Regulus Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.08%
Dec-19-17 08:30AM  Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease PR Newswire
Nov-13-17 06:10PM  Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 06:36PM  Regulus reports 3Q loss Associated Press
04:10PM  Regulus Reports Third Quarter 2017 Financial Results and Recent Events PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 04:15PM  Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017 PR Newswire -7.41%
Oct-03-17 08:53AM  Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session Zacks +6.06%
Aug-30-17 04:15PM  Regulus to Present at the 2017 Wells Fargo Healthcare Conference PR Newswire
Aug-25-17 08:35AM  Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? Zacks -5.88%
Aug-13-17 12:35PM  Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-17 05:00PM  Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-01-17 09:40PM  Regulus reports 2Q loss Associated Press
04:10PM  Regulus Reports Second Quarter 2017 Financial Results and Recent Events PR Newswire
12:15PM  Investor Network: Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 09:15PM  Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares GuruFocus.com
04:05PM  Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
08:30AM  Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 PR Newswire
Jul-19-17 09:45PM  Regulus Announces Pricing of Public Offering of Common Stock PR Newswire
04:01PM  Regulus Announces Commencement of Public Offering of Common Stock PR Newswire
Jun-13-17 02:24PM  Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations SmarterAnalyst
01:12PM  Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip TheStreet.com
08:30AM  Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer PR Newswire
Jun-12-17 07:00AM  Regulus Announces Pipeline Updates and Advancements PR Newswire -16.07%
Jun-08-17 08:00AM  Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics PR Newswire
Jun-01-17 04:15PM  Pascale Witz Joins Regulus Board of Directors PR Newswire
May-17-17 07:05AM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 04:30PM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents -6.06%
May-08-17 08:00AM  Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down Accesswire -5.56%
May-05-17 05:03AM  Regulus reports 1Q loss Associated Press +5.88%
May-04-17 04:30PM  Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring PR Newswire
Apr-27-17 04:10PM  Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017 PR Newswire
Mar-31-17 12:46PM  DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
12:16PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Regulus Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
11:51AM  DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
11:21AM  RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
09:38AM  DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:58AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline PR Newswire
Mar-30-17 04:47PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
01:35PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline GlobeNewswire
11:35AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017 GlobeNewswire
Mar-28-17 03:18PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire -11.76%
12:36PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
08:30AM  Regulus to Present at the 16th Annual Needham Healthcare Conference PR Newswire
Mar-27-17 06:05PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire +21.43%
09:30AM  Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Accesswire
Mar-24-17 11:50AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Accesswire +12.00%
11:28AM  INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:29AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017 Accesswire
Mar-22-17 10:54AM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:46AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Business Wire
Mar-20-17 10:38AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -7.84%
10:28AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017 Accesswire
Mar-17-17 07:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline RGLS GlobeNewswire
10:58AM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:00AM  RGLS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 Business Wire
Mar-15-17 12:32PM  INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -7.14%
10:27AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 Accesswire
Mar-14-17 12:08PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-13-17 12:00PM  RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 PR Newswire +8.00%
Mar-09-17 01:04PM  IMPORTANT ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:27AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017 Accesswire
Mar-08-17 01:04PM  REGULUS THERAPEUTICS INC. Financials +13.04%
12:14PM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:02AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Business Wire
09:00AM  DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact The Firm Business Wire
Mar-06-17 01:20PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-03-17 08:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - RGLS Accesswire
10:23AM  RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 Business Wire
06:09AM  REGULUS THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Mar-02-17 10:14PM  Edited Transcript of RGLS earnings conference call or presentation 2-Mar-17 10:00pm GMT
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.